8 analysts have shared their evaluations of HealthEquity (NASDAQ:HQY) during the recent three months, expressing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	2	5	0	0	1
Last 30D	1	0	0	0	0
1M Ago	0	0	0	0	0
2M Ago	0	1	0	0	1
3M Ago	1	4	0	0	0

Analysts have recently evaluated HealthEquity and provided 12-month price targets. The average target is $118.5, accompanied by a high estimate of $130.00 and a low estimate of $89.00. Experiencing a 4.95% decline, the current average is now lower than the previous average price target of $124.67.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
David Larsen	BTIG	Lowers	Buy	$110.00	$130.00
David Roman	Goldman Sachs	Announces	Sell	$89.00	-
Scott Schoenhaus	Keybanc	Raises	Overweight	$125.00	$120.00
Glen Santangelo	Barclays	Announces	Overweight	$118.00	-
Alexander Paris	Barrington Research	Maintains	Outperform	$125.00	$125.00
Alexei Gogolev	JP Morgan	Raises	Overweight	$129.00	$126.00
Constantine Davides	Citizens	Raises	Market Outperform	$122.00	$117.00
David Larsen	BTIG	Maintains	Buy	$130.00	$130.00

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HealthEquity. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of HealthEquity compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of HealthEquity's stock. This examination reveals shifts in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of HealthEquity's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on HealthEquity analyst ratings.

About HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Financial Insights: HealthEquity

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: HealthEquity's remarkable performance in 3M is evident. As of 31 October, 2025, the company achieved an impressive revenue growth rate of 7.23%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: HealthEquity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.05%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.42%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): HealthEquity's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.52% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: With a below-average debt-to-equity ratio of 0.48, HealthEquity adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Significance of Analyst Ratings Explained

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.